Ideaya Biosciences Inc. (IDYA)
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
The mean of analysts' price targets for IDEAYA Biosciences (IDYA) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive News is Driving This Cancer Drug Maker's Stock Higher
Shares of IDEAYA Biosciences Inc. NASDAQ: IDYA are up more than 16% after announcing positive treatment data for its Phase 2 clinical trial. The company's pipeline candidate, IDE397, is an experimental drug designed to treat certain bladder and small-cell lung cancers.
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?
IDEAYA Biosciences (IDYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IDEAYA Biosciences Soars on Cancer Drug Study Results
Shares of IDEAYA Biosciences (IDYA) took off in intraday trading Monday after the biotech announced positive results in a mid-stage study of its treatment for certain bladder and small-cell lung cancers.
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
Monday, IDEAYA Biosciences Inc IDYA released clinical data for the IDE397 Phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients (NSCLC).
Why Ideaya Biosciences Just Made Its Most Bullish Move Since March
Ideaya Biosciences presented promising results Monday for a drug that tackles hard-to-treat cancers. The biotech stock surged.
